Roth initiates Acura Pharmaceuticals (ACUR +5.8%) at Buy with a $4.50 price target, representing a near 100% upside from Monday's closing price. On the earnings call earlier this month, Roth analyst Robert Cummins Hazlett had a good-natured back-and-forth with management regarding NEXAFED and OXECTA.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs